{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:28:59Z","timestamp":1787678939750,"version":"build-2784847793"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":265,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100465","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T11:45:58Z","timestamp":1632743158000},"page":"100465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Prioritising breast cancer theranostics: A current medical longing in oncology"],"prefix":"10.1016","volume":"29","author":[{"given":"Prem N.","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Sapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dr. Atul","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dr. Amit Kumar","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100465_bib0001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.wpi.2012.07.006","article-title":"Pharmaceutical patent analyst \u2013 FutureScience publishing","volume":"34","author":"Rainey","year":"2012","journal-title":"World Patent Inf."},{"key":"10.1016\/j.ctarc.2021.100465_bib0002","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.nantod.2013.04.001","article-title":"Open-source nanotechnology: solutions to a modern intellectual property tragedy","volume":"8","author":"Pearce","year":"2013","journal-title":"Nano Today"},{"key":"10.1016\/j.ctarc.2021.100465_bib0003","series-title":"The WIPO Manual on Open Source Patent Analytics","author":"Paul Oldham","year":"2016"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100465_bib0004","article-title":"Patent protections, challenges and applications of nanotechnology","volume":"8","author":"Anuar","year":"2013","journal-title":"J. Technol. Operat. Manag."},{"key":"10.1016\/j.ctarc.2021.100465_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.wpi.2019.101943","article-title":"Qualitative and quantitative analysis of patent data in nanomedicine for bridging the gap between research activities and practical applications","volume":"60","author":"Choi","year":"2020","journal-title":"World Patent Information"},{"key":"10.1016\/j.ctarc.2021.100465_bib0006","doi-asserted-by":"crossref","DOI":"10.17485\/ijst\/2016\/v9i24\/96150","article-title":"A study on patent valuation important factors: focus on china industry","volume":"9","author":"Young-Ki","year":"2016","journal-title":"Indian J. Sci. Technol."},{"key":"10.1016\/j.ctarc.2021.100465_bib0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/nnm.10.33","article-title":"Nanosilver and global public health: international regulatory issues","volume":"5","author":"Faunce","year":"2010","journal-title":"Nanomedicine (London, England)"},{"key":"10.1016\/j.ctarc.2021.100465_bib0008","series-title":"Guidelines for Preparing Patent Landscape Reports","article-title":"Guidelines for preparing patent landscape reports","author":"Trippe","year":"2015"},{"key":"10.1016\/j.ctarc.2021.100465_bib0009","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10876-018-01491-7","article-title":"Emerging theranostic biogenic silver nanomaterials for breast cancer: a systematic review","volume":"30","author":"Barabadi","year":"2019","journal-title":"J. Cluster Sci."},{"key":"10.1016\/j.ctarc.2021.100465_bib0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1166\/jbn.2013.1583","article-title":"Nanomaterials in cancer-therapy drug delivery system","volume":"9","author":"Zhang","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ctarc.2021.100465_bib0011","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1021\/acsomega.7b01347","article-title":"Drug-carrying capacity and anticancer effect of the folic acid- and berberine-loaded silver nanomaterial to regulate the akt-erk pathway in breast cancer","volume":"3","author":"Bhanumathi","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ctarc.2021.100465_bib0012","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1038\/s41467-021-23959-3","article-title":"Rapid custom prototyping of soft poroelastic biosensor for simultaneous epicardial recording and imaging","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2021.100465_bib0013","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2021.100465_bib0014","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ctrv.2013.03.009","article-title":"Targeting the PI3K\/AKT\/mTOR and Raf\/MEK\/ERK pathways in the treatment of breast cancer","volume":"39","author":"Saini","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2021.100465_bib0015","series-title":"Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer","first-page":"12","author":"Fang","year":"2021"},{"key":"10.1016\/j.ctarc.2021.100465_bib0016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ddmec.2004.09.002","article-title":"Mechanisms of breast cancer","volume":"1","author":"Imyanitov","year":"2004","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.ctarc.2021.100465_bib0017","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.ctarc.2021.100465_bib0018","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/967419","article-title":"Multidrug resistance in breast cancer: from in vitro models to clinical studies","volume":"2011","author":"Wind","year":"2011","journal-title":"Int. J. Breast Cancer"},{"key":"10.1016\/j.ctarc.2021.100465_bib0019","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","article-title":"Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling","volume":"22","author":"Clarke","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2021.100465_bib0020","doi-asserted-by":"crossref","DOI":"10.1088\/2516-1091\/abaaa3","article-title":"Optical spectroscopy for in vivo medical diagnosis\u2014a review of the state of the art and future perspectives","volume":"2","author":"Kim","year":"2020","journal-title":"Prog. Biomed. Eng."},{"key":"10.1016\/j.ctarc.2021.100465_bib0021","series-title":"Theranostic Agents","first-page":"60","author":"Benzhong Tang","year":"2017"},{"key":"10.1016\/j.ctarc.2021.100465_bib0022","series-title":"Biomarkers for Theranostics, Caris Life Sciences Switzerland Holdings GmbH","first-page":"342","author":"Halbert","year":"2015"},{"key":"10.1016\/j.ctarc.2021.100465_bib0023","doi-asserted-by":"crossref","first-page":"E1278","DOI":"10.1073\/pnas.1421229112","article-title":"Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance","volume":"112","author":"Conde","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ctarc.2021.100465_bib0024","series-title":"Methods For Diagnosis, Prognosis And Treatment Of Primary And Metastatic Basal-Like Breast Cancer And Other Cancertypes","first-page":"63","author":"Partha","year":"2015"},{"key":"10.1016\/j.ctarc.2021.100465_bib0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ctrv.2011.11.005","article-title":"Molecular biology in breast cancer: intrinsic subtypes and signaling pathways","volume":"38","author":"Eroles","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2021.100465_bib0026","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10961-007-9076-5","article-title":"Mapping the nanotechnology enterprise: a multi-indicator analysis of emerging nanodistricts in the US South","volume":"33","author":"Youtie","year":"2008","journal-title":"J. Technol. Transfer"},{"key":"10.1016\/j.ctarc.2021.100465_bib0027","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1515\/jbvela-2016-0002","article-title":"Patent valuation with forecasts of forward citations","volume":"12","author":"Falk","year":"2017","journal-title":"J. Bus. Valuation Econ. Loss Anal."},{"key":"10.1016\/j.ctarc.2021.100465_bib0028","unstructured":"M. Gagliardi, \"Theranostics: global markets\", in: M. Gagliardi (Ed.) BIO198A Theranostics: Global Markets, BCC Research LLC, Boston, USA, 2020, pp. 160."},{"key":"10.1016\/j.ctarc.2021.100465_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-020-00845-4","article-title":"How cancer genomics is transforming diagnosis and treatment_Nature.pdf","volume":"579","author":"Nogrady","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2021.100465_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.est.2021.102335","article-title":"Poly-4-methyl-1-pentene a dielectric material: Patent landscape","volume":"36","author":"Ghule","year":"2021","journal-title":"J. Energy Storage"},{"key":"10.1016\/j.ctarc.2021.100465_bib0031","series-title":"Therapeutic Oligonucleotide","first-page":"386","author":"Heather O'NEILL","year":"2016"},{"key":"10.1016\/j.ctarc.2021.100465_bib0032","series-title":"Caris Life Sciences Switzerland Holdings GmbH","first-page":"342","article-title":"Biomarkers for theranostics","author":"David","year":"2015"},{"key":"10.1016\/j.ctarc.2021.100465_bib0033","series-title":"Caris Life Sciences Switzerland Holdings GMBH","first-page":"219","article-title":"Aptamers and uses thereof","author":"David HALBERT","year":"2018"},{"key":"10.1016\/j.ctarc.2021.100465_bib0034","doi-asserted-by":"crossref","first-page":"e3045","DOI":"10.1038\/cddis.2017.440","article-title":"Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers","volume":"8","author":"Hamam","year":"2017","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ctarc.2021.100465_bib0035","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.ctarc.2021.100465_bib0036","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.tibtech.2010.07.005","article-title":"Targeting cancer cells with nucleic acid aptamers","volume":"28","author":"Cerchia","year":"2010","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ctarc.2021.100465_bib0037","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7150\/thno.10202","article-title":"Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine","volume":"5","author":"Xiang","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.ctarc.2021.100465_bib0038","doi-asserted-by":"crossref","first-page":"34","DOI":"10.32607\/20758251-2013-5-4-34-43","article-title":"Aptamers: problems, solutions and prospects","volume":"5","author":"Lakhin","year":"2013","journal-title":"Acta Naturae"},{"key":"10.1016\/j.ctarc.2021.100465_bib0039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nature reviews. Drug discovery"},{"key":"10.1016\/j.ctarc.2021.100465_bib0040","series-title":"CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS","first-page":"695","article-title":"Circulating Biomarkers","author":"Spetzler","year":"2012"},{"key":"10.1016\/j.ctarc.2021.100465_bib0041","series-title":"Caris Life Sciences Luxembourg Holdings","first-page":"584","article-title":"Circulating biomarkers for disease","author":"Kuslich","year":"2011"},{"key":"10.1016\/j.ctarc.2021.100465_bib0042","series-title":"Caris Life Sciences Luxembourg Holdings","first-page":"456","article-title":"Biomarkers for theranostics","author":"Halbert","year":"2011"},{"key":"10.1016\/j.ctarc.2021.100465_bib0043","series-title":"Caris Life Sciences Luxembourg Holdings","first-page":"456","article-title":"Biomarkers for theranostics","author":"Halbert","year":"2016"},{"key":"10.1016\/j.ctarc.2021.100465_bib0044","series-title":"Caris Life Sciences Luxembourg Holdings","first-page":"639","article-title":"Circulating biomarkers for disease","author":"Spetzler","year":"2012"},{"key":"10.1016\/j.ctarc.2021.100465_bib0045","series-title":"Caris Life Sciences Luxembourg Holdings","first-page":"410","article-title":"Biomarker compositions and methods","author":"Brown","year":"2013"},{"key":"10.1016\/j.ctarc.2021.100465_bib0046","series-title":"Caris Life Sciences Luxembourg Holdings","article-title":"Biomarker compositions and methods","author":"Brown","year":"2012"},{"key":"10.1016\/j.ctarc.2021.100465_bib0047","series-title":"Centre National De La Recherche Scientifique","first-page":"128","article-title":"Analytical methods for cell free nucleic acids and applications","author":"Thierry","year":"2012"},{"key":"10.1016\/j.ctarc.2021.100465_bib0048","series-title":"Caris Life Sciences Switzerland Holdings GmbH Caris Life Sciences Luxembourg Holdings","first-page":"193","article-title":"Biomarker compositions and methods","author":"Brown","year":"2014"},{"key":"10.1016\/j.ctarc.2021.100465_bib0049","series-title":"Biomarker Compositions And Methods","first-page":"324","author":"SCHETTINI","year":"2015"},{"key":"10.1016\/j.ctarc.2021.100465_bib0050","series-title":"Caris Life Sciences Switzerland Holdings GmbH Caris Life Sciences Luxembourg Holdings","first-page":"507","article-title":"Circulating biomarkers","author":"Spetzler","year":"2014"},{"key":"10.1016\/j.ctarc.2021.100465_bib0051","series-title":"Methods For Data Collection And Distribution","author":"Giusti","year":"2013"},{"key":"10.1016\/j.ctarc.2021.100465_bib0052","series-title":"Biomarker Compositions And Methods","first-page":"464","author":"SCHETTINI","year":"2014"},{"key":"10.1016\/j.ctarc.2021.100465_bib0053","series-title":"Biomarker Methods and Compositions","first-page":"412","author":"Maney","year":"2014"},{"key":"10.1016\/j.ctarc.2021.100465_bib0054","series-title":"Psma Ligands And Uses Thereof","first-page":"64","author":"Basilion","year":"2014"},{"key":"10.1016\/j.ctarc.2021.100465_bib0055","series-title":"Caris Life Sciences Switzerland Holdings GmbH Caris Life Sciences Luxembourg Holdings","first-page":"289","article-title":"Bomarker compositions and markers","author":"Brown","year":"2012"},{"key":"10.1016\/j.ctarc.2021.100465_bib0056","series-title":"Microbiota Composition, As a Marker Of Responsiveness to ANTI-PD1\/PD-L1\/PD-L2 Antibodies and Use Of Microbial Modulators for Improving The Efficacy Of An ANTI-PD1\/PD-L1\/PD-L2 AB-Based Treatment","author":"Zitvogel","year":"2018"},{"key":"10.1016\/j.ctarc.2021.100465_bib0057","series-title":"Caris Life Sciences Switzerland Holdings GmbH","first-page":"340","article-title":"Vescle isolation methods","author":"Spetzler","year":"2012"},{"key":"10.1016\/j.ctarc.2021.100465_bib0058","series-title":"Nir Materials and Nanomaterials for Theranostic Applications","first-page":"24","author":"Brown","year":"2013"},{"key":"10.1016\/j.ctarc.2021.100465_bib0059","series-title":"Aptamers and Uses Thereof","author":"Halbert","year":"2014"},{"key":"10.1016\/j.ctarc.2021.100465_bib0060","series-title":"Caris Life Sciences Switzerland Holdings GmbH","first-page":"473","article-title":"Circulating biomarkers for metastatic prostate cancer","author":"Kuslich","year":"2016"},{"key":"10.1016\/j.ctarc.2021.100465_bib0061","series-title":"Intraperitoneally-Administered Nanocarriers That Release Their Therapeutic Load Based on the Inflammatory Environment of Cancers","first-page":"59","author":"Zeinelden","year":"2013"},{"key":"10.1016\/j.ctarc.2021.100465_bib0062","series-title":"Caris Life Sciences Switzerland Holdings GmbH Caris Life Sciences Luxembourg Holdings SARL","first-page":"126","article-title":"Circulating biomarkers for cancer","author":"Pawlowski","year":"2014"},{"key":"10.1016\/j.ctarc.2021.100465_bib0063","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1158\/1078-0432.CCR-07-1393","article-title":"Delta-like 4\/Notch Signaling and Its Therapeutic Implications","volume":"13","author":"Yan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100465_bib0064","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2021.100465_bib0065","doi-asserted-by":"crossref","first-page":"877","DOI":"10.7150\/jca.11735","article-title":"Argonaute 2: a novel rising star in cancer research","volume":"6","author":"Ye","year":"2015","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2021.100465_bib0066","article-title":"Galectin-3 as a marker and potential therapeutic target in breast cancer","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2021.100465_bib0067","first-page":"3070","article-title":"Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer","volume":"49","author":"Ring","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100465_bib0068","first-page":"1197","article-title":"Expression and clinical significance of Gal-3 and NF\u03baB pathway-related factors in epithelial ovarian carcinoma","volume":"13","author":"Luk","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ctarc.2021.100465_bib0069","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1710020","article-title":"Phenotypic analysis of extracellular vesicles: a review on the applications of fluorescence","volume":"9","author":"Panagopoulou","year":"2020","journal-title":"J. Extracellular Vesicles"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100465_bib0070","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","article-title":"Biomarkers: Potential uses and limitations","author":"Mayeux","year":"2004","journal-title":"NeuroRX"},{"key":"10.1016\/j.ctarc.2021.100465_bib0071","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/onc.2017.48","article-title":"FOXC1: an emerging marker and therapeutic target for cancer","volume":"36","author":"Han","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2021.100465_bib0072","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1002\/jcp.29339","article-title":"PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells","volume":"235","author":"Afsharzadeh","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ctarc.2021.100465_bib0073","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.3389\/fimmu.2019.02989","article-title":"Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy","volume":"10","author":"Shui","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2021.100465_bib0074","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8545347","article-title":"Isolation of extracellular vesicles: general methodologies and latest trends","volume":"2018","author":"Konoshenko","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ctarc.2021.100465_bib0075","series-title":"Therapeutic Oligonucleotide","first-page":"386","author":"Heather O'NEILL","year":"2016"},{"key":"10.1016\/j.ctarc.2021.100465_bib0076","series-title":"Targeted Oligonucleotides","first-page":"427","author":"Heather O'NEILL","year":"2017"},{"key":"10.1016\/j.ctarc.2021.100465_bib0077","series-title":"Caris Life Sciences Switzerland Holdings GMBH","first-page":"219","article-title":"Nianqing Xiao, aptamers and uses thereof","author":"HALBERT","year":"2018"},{"key":"10.1016\/j.ctarc.2021.100465_bib0078","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3389\/fimmu.2019.00865","article-title":"Is the complement protein C1q a pro- or anti-tumorigenic factor? Bioinformatics analysis involving human carcinomas","volume":"10","author":"Mangogna","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2021.100465_bib0079","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fimmu.2015.00317","article-title":"Emerging and novel functions of complement protein C1q","volume":"6","author":"Kouser","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2021.100465_bib0080","doi-asserted-by":"crossref","first-page":"e15787","DOI":"10.1371\/journal.pone.0015787","article-title":"Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization","volume":"5","author":"Hovanessian","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2021.100465_bib0081","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/1574892808666131119095953","article-title":"Cell surface nucleolin as a target for anti-cancer therapies","volume":"9","author":"Marina","year":"2014","journal-title":"Recent Patents Anti-Cancer Drug Discovery"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:20:52Z","timestamp":1762842052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":81,"alternative-id":["S2468294221001611"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100465","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prioritising breast cancer theranostics: A current medical longing in oncology","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100465"}}